

## VIII Conference of the Pan American Network on Drug Regulatory Harmonization (CPANDRH), Mexico City.

## **Regulatory Convergence for Universal Health**

Building Capacity, Expanding Access and Facilitating Regulatory Cooperation in the Region of the Americas.

Date: October 19<sup>th</sup>-21<sup>st</sup> 2016

**Venue:** Secretaría de Relaciones Exteriores- SRE (Ministry of Foreign Affairs of Mexico), José María Morelos y Pavón Room, 1<sup>st</sup> Floor, Plaza Juárez Nº 20, Colonia Centro, Delegación Cuauhtémoc, Mexico City.

PRE REGISTRATION				
	October 18 <sup>th</sup> 18:00-20:00			
	<b>/stal</b> , 1 <sup>st</sup> Floor.			
Venue: P	aseo de la Reforma No.1, Colonia Tabacalera, Delegación Cuauhtémoc, Mexico City.			
	Day 1. October 19 <sup>th</sup>			
7:30	Registration			
	Secretaría de Relaciones Exteriores, main entrance.			
	Opening ceremony:			
	Welcome video - Dr. Carissa Etienne, PAHO/WHO Director			
	Julio Sánchez y Tépoz, Federal Commissioner for Protection against Sanitary Risks			
8:30	(COFEPRIS)			
0.50	Gerry Eijkemans, PAHO/WHO Representative Mexico			
	Mikel Arriola, General Director of Mexican Social Security Institute (IMSS)			
	The role of regulatory systems for medicines and other health technologies in Universal			
	Health (James Fitzgerald – PAHO/WHO HSS Director)			
	José Narro Robles, Mexico Secretary of Health			
	PANDRH Secretariat Report: Update and progress since the VII Conference regarding			
9:30	implementation of the PANDRH Strategic Plan 2014-2020; Objectives of the VIII Conference			
	(Analía Porrás, PAHO/WHO)			
	Thematic Session 1: Harmonization , convergence, cooperation and exchange of experiences,			
	and reliance			
	Moderators:			
10:00	Julio Sánchez y Tépoz, Cofepris – Mexico			
	Andrea Grimes, Ministry of Health – Trinidad & Tobago			
	Procentation DANDRU Secretariat. The role of harmonization convergence and reliance on the			
	Presentation - PANDRH Secretariat: The role of harmonization, convergence and reliance on the development and strengthening of regulatory systems in the Americas.			
	Tools and standards			
	Opportunities for the adoption of common standards (Maria Luz Pombo, PAHO/WHO)			

SALUD SECRETARIA DE S					
	<ul> <li>Partner and donors: Bill and Melinda Gates Foundation (Murray Lumpkin, BMG Foundation)</li> <li>Short Case Study: Implementation of the International Standards Organization (ISO) for the Identification of Medical Products (IDMP) (Joan Blair, FDA, USA)</li> <li>The benefits of convergence with international standards (Jaime Oliveira, BAYER FIFARMA)</li> </ul>				
	DEBATE				
11:00	Coffee break				
	Thematic Session 1: Harmonization , convergence, cooperation and exchange of experiences, and reliance Moderators: Maryam Hinds, Barbados Drug Service Beatriz Luna, Ministerio de Salud Pública de Uruguay				
11:30	<ul> <li>Reliance to strengthen regulatory systems         <ul> <li>National experiences: El Salvador (José Vicente Coto, DNM)</li> <li>International experiences: IMDRF, MDSAP and REPS (Fabio Pereira Quintino, ANVISA, Brazil) IGDRP (Mariana Gebara-Coghlan, TGA, Australia) ICH (Lenita Lindström-Gommers, ICH)</li> </ul> </li> </ul>				
12:45	DEBATE         Thematic Session 2: Core regulatory functions and innovative operating models         Moderators         María Angélica Sánchez, INVIMA         Vanria Rolle, Director Bahamas National Drug Agency         • The role of the evaluation tool in implementing core regulatory functions (José Peña, PAHO/WHO)         • Caribbean Regulatory System         CARPHA perspective (Lucette Cargil, Caribbean Public Health Agency)         Country perspective: Suriname (Miriam Naarendorp, Ministry of Health Suriname)         • Pacific Alliance (Biby Ferrada, ISP, Chile)         DEBATE				
13:30	Lunch				
13:30 - 14:30	PANDRH Steering Committee Meeting Lunch (Private Meeting - Room "Benito Juárez", 1 <sup>st</sup> floor)				





14:30       Moderation, questions, summary Catherine Parker, BGTD, Health Canada / Juan Carlos Gallaga, COFEPRIS, Mexico Dulce Maria Martinez, CECMED, Cuba / Maria Angélica Sánchez, INVIMA, Colombia         **Important note: for this session, the rooms will be split         15:45       PANELS – priority themes         PANEL A: MEDICAL DEVICES (Section C – José Maria Morelos Room)       PANEL B: ACCESS AND RATIONAL USI (Sections AB - José Maria Morelos Room)         0       Overview of the Medical Devices regulation in the Region of the Americas (Dulce Maria Martinez, CECMED, Cuba)       PANEL B: ACCESS AND RATIONAL USI (Sections AB - José Maria Morelos Room)         0       Overview of the Region of the Americas (Dulce Maria Martinez, CECMED, Cuba)       PANEL B: ACCESS AND RATIONAL USI (Sections AB - José Maria Morelos Room)         0       Overview of the Region (Elkin Hernán Otdivaro Cfuentes – INVIMA, Colombio)       The orle of the regulation in the access and rational use of medicales         0       Short case study: the risk-based regulation of medical devices in Mexico DEBATE Moderator: Alexandre Lemgruber, PAHO/WHO       The strategy against antimicrobials resistance: the regulation of autors, COFEPRIS, Mexico)         0       DEBATE Moderator: Alexandre Lemgruber, PAHO/WHO       DEBATE         16:45       Coffee break         PANEL C: MEDICAL PRODUCTS OF HUMAN ORIGIN AND OTHER BIOLOGICALS (Section C – José Maria Morelos Room) = Participation of different actors in the regulation of some health technologies: Blood and blood products : the regulatory plurality       PANEL D: POST-MARK		Commande Federal pare la Prefercida Contra Responsibilitation Discussion Groups	seaw Americas		
15:45       PANELS – priority themes         PANEL A: MEDICAL DEVICES (Section C – José María Morelos Room)         • Overview of the Medical Devices regulation in the Region of the Americas (Dulce Maria Martinez, CECMED, Cubo)       PANEL B: ACCESS AND RATIONAL USI (Sections AB - José María Morelos Roon)         • The implementation of technovigilance in the Region (Elkin Hernán Otólvaro Cifuentes - INVIMA, Colombia)       The role of the regulation in the access and rational use of medicines         • OTC: control of places and conditio sale (Sebastián Duarte, ANMAT, Arget regulation of medical devices in Mexico (Rocio Alatorre, COFEPRIS, Mexico)       • OTC: control of places and conditio sale (Sebastián Duarte, ANMAT, Arget Moderator: Alexandre Lemgruber, PAHQ/WHO         16:45       Coffee break         PANEL C: MEDICAL PRODUCTS OF HUMAN ORIGIN AND OTHER BIOLOGICALS (Section C – José María Morelos Room)       DEBATE Moderator: José María Morelos Room)         • Participation of different actors in the regulation of some health technologies: Blood and blood products : the regulation challenges faced by NRAs Maria Teresa Ibarz, INHRR, Venezuela Joao Batista da Silva Junior, ANVISA, Brazil       • Traceability systems (Maria José Sánchez ANMAT, Argentina)         17:15       DEBATE Moderator: Maria da Silva Junior, ANVISA, Brazil       • Marta Teresa Ibarz, INHRR, Venezuela Joao Batista da Silva Junior, ANVISA, Brazil         17:15       DEBATE Moderator: Maria Lus Bench Bablica Device Reports fro RNAs of the Region of the Americas (Du Maria Martinez, CECMED, Cuba)	14:30	Moderation, questions , summary Catherine Parker, BGTD, Health Canada / Juan Carlos Gallaga, COFEPRIS, Mexico			
<ul> <li>PANEL A: MEDICAL DEVICES         <ul> <li>Section C – José María Morelos Room)</li> <li>Overview of the Medical Devices             regulation in the Region of the             Americas (Dulce María Martinez,             CECMED, Cuba)</li> <li>The implementation of             technovigilance in the Region (Elkin             Hernán Otálvaro Cifuentes – INVIMA,             Colombia)</li> <li>Short case study: the risk-based             regulation of medical devices in             Mexico)             DEBATE             Moderator: Alexandre Lemgruber, PAHO/WHO</li> </ul> </li> <li>16:45         <ul> <li>PANEL B: ACCESS AND RATIONAL USI             (Sections AB - José María Morelos Room)</li> <li>OTC: control of places and conditio             sale (Sebastián Duarte, ANMAT, Argei             regulation of medical devices in             Mexico)             DEBATE             Moderator: Alexandre Lemgruber, PAHO/WHO</li> </ul> </li> <li>16:45         <ul> <li>Panel C: MEDICAL PRODUCTS OF HUMAN             ORIGIN AND OTHER BIOLOGICALS             (Sections C – José María Morelos Room)</li> <li>Participation of different actors in the             regulation of some health technologies:             Blood and blood products : the regulation             chalter Arias, Health Canada;             Joao Batista da Silva Junior, ANVISA, Brazil         <ul> <li>The areactive pharmacovigilance             - market withdrawal of medicati             (Juan Roldón, ISP, Chile)</li> <li>Successful experiences in coordination             public health programs (Lazaro Eduardo             Berroma, Cofepris, Mexico)         <ul> <li>DEBATE</li> <li>Gene therapy and cell therapy: regulation             chalterapy and cell therapy: regulation             chalterapy and cell therapy: regulation             chalterapy and cell therapy: regulation</li></ul></li></ul></li></ul></li></ul>		*Important note: for this session, the rooms will be split			
<ul> <li>(Section C – José María Morelos Room)         <ul> <li>Overview of the Medical Devices regulation in the Region of the Americas (<i>Duice Maria Martinez, CECMED, Cuba</i>)</li> <li>The implementation of technovigilance in the Region (<i>Elkin Hemán Otálvaro Cifuentes – INVIMA, Colombia</i>)</li> <li>The role of the regulation of places and conditio sale (<i>Sebastián Duarte, ANMAT, Argentechnov Cifuentes – INVIMA, Colombia</i>)</li> <li>Short case study: the risk-based regulation of medical devices in Mexico (<i>Rocio Alatorre, COFEPRIS, Mexico</i>)</li> </ul> </li> <li>DEBATE Moderator: <i>Alexandre Lemgruber, PAHO/WHO</i></li> <li>16:45 Coffee break</li> <li>PANEL C: MEDICAL PRODUCTS OF HUMAN ORIGIN AND OTHER BIOLOGICALS (Section C – José María Morelos Room)</li> <li>Participation of different actors in the regulation of some health technologies: Blood and blood products : the regulation of able <i>Diso Batista da Silva Junior, ANVISA, Brazil Jaoa Batista da Silva Junior, ANVIS</i></li></ul>	15:45				
16:45       Coffee break         16:45       Coffee break         PANEL C: MEDICAL PRODUCTS OF HUMAN ORIGIN AND OTHER BIOLOGICALS (Section C – José María Morelos Room)       PANEL D: POST-MARKET SURVEILLANG (Sections AB - José María Morelos Roo         • Participation of different actors in the regulation of some health technologies: Blood and blood products : the regulatory plurality Ariel Arias, Health Canada; Joao Batista da Silva Junior, ANVISA, Brazil       • Traceability systems (María José Sánchez ANMAT, Argentina)         17:15       Gene therapy and cell therapy: regulation challenges faced by NRAs Maria Teresa Ibarz, INHRR, Venezuela Joao Batista da Silva Junior, ANVISA, Brazil       • Successful experiences in coordination public health programs (Lazaro Eduardo Berumen, Cofepris, Mexico)         • DEBATE Modematara, Maria Lun Bamba, DALLO (MUDO)       • DEBATE		<ul> <li>(Section C – José María Morelos Room)         <ul> <li>Overview of the Medical Devices regulation in the Region of the Americas (Dulce María Martínez, CECMED, Cuba)</li> <li>The implementation of technovigilance in the Region (Elkin Hernán Otálvaro Cifuentes – INVIMA, Colombia)</li> <li>Short case study: the risk-based regulation of medical devices in Mexico (Rocío Alatorre, COFEPRIS, Mexico)</li> </ul> </li> <li>DEBATE</li> </ul>	<ul> <li>OTC: control of places and conditions of sale (Sebastián Duarte, ANMAT, Argentina)</li> <li>The strategy against antimicrobials resistance: the regulation of antibiotics Brazil short case study (Christiane Santiago Maia, ANVISA) El Salvador short case study (José Vicente Coto, DNM, El Salvador)</li> <li>DEBATE</li> </ul>		
<ul> <li>PANEL C: MEDICAL PRODUCTS OF HUMAN ORIGIN AND OTHER BIOLOGICALS (Section C – José María Morelos Room)</li> <li>Participation of different actors in the regulation of some health technologies: Blood and blood products : the regulatory plurality Ariel Arias, Health Canada; Joao Batista da Silva Junior, ANVISA, Brazil</li> <li>Gene therapy and cell therapy: regulation challenges faced by NRAs Maria Teresa Ibarz, INHRR, Venezuela Joao Batista da Silva Junior, ANVISA, Brazil</li> <li>DEBATE DEBATE Madaratory, Maria Luz Dambo, DAUO (MUDO)</li> <li>PANEL D: POST-MARKET SURVEILLANG (Sections AB - José María Morelos Roo (Sections AB - José María Morelos Roo</li> <li>Traceability systems (María José Sánchez ANMAT, Argentina)</li> <li>Pharmacovigilance in the Region: - periodic safety update report - active pharmacovigilance - market withdrawal of medicati (Juan Roldón, ISP, Chile)</li> <li>Successful experiences in coordination public health programs (Lazaro Eduardo Berumen, Cofepris, Mexico)</li> <li>The implementation of REDMA Exchan Program in Medical Device Reports fro RNAs of the Region of the Americas (Du María Martínez, CECMED, Cuba)</li> </ul>	16:45				
Mederatory Maria Luz Dombo DALIO (M/LO		<ul> <li>PANEL C: MEDICAL PRODUCTS OF HUMAN ORIGIN AND OTHER BIOLOGICALS (Section C – José María Morelos Room)</li> <li>Participation of different actors in the regulation of some health technologies: Blood and blood products : the regulatory plurality <i>Ariel Arias, Health Canada;</i> <i>Joao Batista da Silva Junior, ANVISA, Brazil</i></li> <li>Gene therapy and cell therapy: regulation challenges faced by NRAs <i>Maria Teresa Ibarz, INHRR, Venezuela</i></li> </ul>	<ul> <li>PANEL D: POST-MARKET SURVEILLANCE (Sections AB - José María Morelos Room)</li> <li>Traceability systems (María José Sánchez, ANMAT, Argentina)</li> <li>Pharmacovigilance in the Region:         <ul> <li>periodic safety update report</li> <li>active pharmacovigilance</li> <li>market withdrawal of medications (Juan Roldón, ISP, Chile)</li> </ul> </li> <li>Successful experiences in coordination with public health programs (Lazaro Eduardo Avila Berumen, Cofepris, Mexico)</li> <li>The implementation of REDMA Exchange Program in Medical Device Reports from RNAs of the Region of the Americas (Dulce</li> </ul>		
18:15 Official photo – Main Stairs of the Ministry of Foreign Affairs		Moderator: Maria Luz Pombo, PAHO/WHO	Moderator: José Luis Castro, PAHO/WHO		

N





	examples Americas				
	&				
	Reception – Terrace of the Ministry of Foreign Affairs (2 <sup>nd</sup> floor)				
	Day 2, October 20 <sup>th</sup>				
8:00	<ul> <li>Private session for NRAs:</li> <li>Harmonization of regulatory capacity assessment tool (<i>Samvel Azatyan, WHO</i>)</li> <li>Regional cooperation initiatives: mechanisms for better coordination (<i>José Peña, PAHO/WHO</i>)</li> <li>DEBATE</li> </ul>				
	Thematic Session 3: Competence in good regulatory practices and regulatory science				
	Moderators: Catherine Parker, Biologics and Genetic Therapies – Health Canada Maria Auxiliadora Vargas de Dentice, Dirección Nacional de Vigilancia Sanitaria - Paraguay Cooperative models between regulator and regulated stakeholders				
	Pharmaceutical perspectives Alfredo Antia, ALIFAR				
0.20	Alexis José Serlin, CANIFARMA				
9:30	<ul> <li>National experiences : Periodic meetings &amp; regulatory education for industry (<i>Patricia Pineda, FDA, USA</i>) Cuba short case (<i>Dulce María Martínez, CECMED, Cuba</i>)     </li> </ul>				
	<ul> <li>International experiences         <ul> <li>The European Medicines Agency (<i>Riccardo Luigetti, EMA</i>)</li> <li>Agencia Española de Medicamentos y Productos Sanitarios (<i>Belén Crespo Sánchez-Eznarriaga, AEMPS</i>)</li> </ul> </li> <li>DEBATE</li> </ul>				
11:00	Coffee break				
	Thematic Session 3: Competence in good regulatory practices and regulatory science				
11:30	<ul> <li>Moderators: Edmundo Garcia, FDA, USA Beatriz Eugenia Batrez Rivera, Ministerio de Salud Pública y Asistencia Social – Guatemala     </li> <li>Presentation – PANDRH Secretariat: Adoption and implementation of prioritization model for PANDRH operation (Murilo Freitas Dias, PAHO/WHO)         <ul> <li>Global regulatory curriculum (Silvia Bendiner, RAPS) Cooperation between academy / regulatory authority in training (capacity building) models (Maria Teresa Ibarz, INHRR, Venezuela)             <ul> <li>Centers of Excellence (Samvel Azatyan, WHO)</li> </ul> </li> </ul></li></ul>				
	DEBATE				
13:30	Lunch				
	Discussion Groups TS3				
14:30	Objective: discussion and recommendations for the concept note TS3 (for the consideration of the conference) Moderators (guide questions & summary): Edmundo Garcia, FDA / Mario Alanis – COFEPRIS, Mexico Cammilla Horta – ANVISA / Philip Budashewitz, FDA, USA				

h

1

SALUD SCRITARIA DE SALUD SCRITARIA DE SALUD			
	*Important note: for this session, the rooms wil	l be split	
15:45	PANEL E: QUALITY MANAGEMENT (Sections AB - José María Morelos Room)         Quality Management Systems (QMS):         • NRA perspectives Pablo Ortíz (ISP, Chile) Dalia Castillo(MoH, Dominican Republic)         • Industry perspectives Gilfredo Navarro (J&J  FIFARMA) Elmer Torres (ALIFAR)	<ul> <li>PANEL F: EMERGENCY PREPAREDNESS natural disasters, epidemiological emergencies (Section C – José María Morelos Room)</li> <li>International mobilization: public health emergencies of international importance (H1N1, Zika) (Patricia Oliveira Pereira Tagliari, ANVISA, Brazil)</li> <li>Regulatory approval and health technology granted in emergencies and special situations: case presentation (drugs, vaccines and clinical trials) Pamela Milla, ISP – Chile Patricio Ocampo, Agencia Nacional de Bagulasión Control y Viailancia Sanitaria</li> </ul>	
46.45	DEBATE Moderator: <i>Murilo Freitas, PAHO/WHO</i>	Regulación, Control y Vigilancia Sanitaria - Ecuador DEBATE Moderator: Jose Peña, PAHO/WHO	
16:45		ee break	
17:15	Rapporteurs discussion groups' session	- Cub - J.	
18:30	Day 3. Octobe	of the day	
	Thematic Session 4: Investment Case for Regula		
8:00	<ul> <li>Moderators:         <ul> <li>Patricia Oliveira Pereira Tagliari, ANVISA, Brazil</li> <li>Danini Contreras, Ministry of Health – Belize</li> </ul> </li> <li>Generics: the added value of incorporation into the health system (Julio Sánchez y Tépoz, COFEPRIS)</li> </ul>		
	<ul> <li>Falsified drugs : the cost to health systems (María José Sánchez, ANMAT, Argentina)</li> <li>PDUFA   GDUFA (Khyati Roberts, AbbVie   FIFARMA)</li> <li>Health surveillance model: a risk-based approach – IVC SOA (Elkin Hernán Otálvaro Cifuentes – INVIMA, Colombia)</li> <li>DEBATE</li> </ul>		
9:30	Conclusions and adoption of the recommendati	ons of the VIII CPARF	
10:00	Closing of the Conference		